PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092654
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092654
Histopathology Testing Equipment Market size was valued at US$ 7,880.3 Million in 2025, expanding at a CAGR of 5.6% from 2026 to 2033.
Histopathology laboratories are rapidly transitioning toward automated and digitally integrated workflows as rising cancer incidence of cancer increases demand for accurate tissue diagnosis. In 2025, hospitals and other healthcare facilities will expand pathology labs through digitalization, AI-assisted image analysis, and standardized pathology workflows to ensure consistent diagnostic quality and reliable outcomes. Equipment manufacturers are introducing integrated platforms that combine tissue processing, staining, slide scanning, and laboratory information management to streamline workflows and reduce manual intervention. Procurement strategies are increasingly evolving from the acquisition of standalone instruments toward integrated laboratory ecosystems that deliver standardized workflows, enhanced quality assurance, seamless digital connectivity, and greater operational efficiency. This shift reflects the growing emphasis on precision oncology, laboratory automation, and the need to mitigate skilled workforce shortages while supporting higher diagnostic throughput.
Histopathology Testing Equipment Market- Market Dynamics
Growing Adoption of AI-Enabled Digital Pathology
Artificial intelligence is becoming a core component in digital pathology laboratories as healthcare systems prioritize diagnostic consistency, workflow efficiency, and faster cancer diagnosis. The increasing global cancer burden, with 20 million cases in 2022, continues to drive demand for high-throughput histopathology services. Regulatory support is accelerating adoption, with the U.S. Food and Drug Administration (FDA) expanding the number of authorized AI-enabled medical devices and approving additional digital pathology platforms, including Roche's high-capacity VENTANA DP 600 scanners in 2025 for primary diagnosis workflows. Meanwhile, companies such as Leica Biosystems, Roche, Fujifilm, and Agilent are strengthening their digital pathology portfolios by integrating AI-driven image analysis, whole-slide imaging, and laboratory information management capabilities, enabling greater workflow standardization, enhanced productivity, and more scalable pathology operations.
The Global Histopathology Testing Equipment Market is segmented on the basis of Product Type, Application, Product Form Factor, Technology, End User, and Region.
Product demand rapidly shifting towards automated histopathology workflows, rather than standalone instruments. Tissue processors remain the largest product segment because standardized fixation and processing underpin diagnostic accuracy across all pathology laboratories. Slide scanners are also rapidly growing as laboratories begin using pathology more frequently. The U.S. FDA has authorized multiple whole-slide imaging systems for primary diagnosis, supporting broader clinical implementation of digital pathology. Leading companies such as Roche, Leica Biosystems, and Hamamatsu Photonics are making scanners that utilize artificial intelligence and workflow automation platforms reflecting rising investment in pathology laboratories and integrated diagnostic ecosystems.
Cancer diagnostics account largest application segment in histopathology, driven by increasing demand for biopsies, cancer screening programs, and precision oncology initiatives requiring standardized tissue processing. The World Health Organization states that in 2022 there were 20 million new cancer cases and 9.7 million cancer deaths worldwide, reinforcing sustained demand for histopathology services. Governments enhancing diagnostic technologies through national cancer control plans and research institutions are expanding biomarker discovery. Companies, such as Agilent Technologies and PHC Holdings Corporation are improving their pathology products to better support medicine and advanced diagnostics that utilize tissue.
Histopathology Testing Equipment Market- Geographical Insights
North America dominates the market for histopathology testing equipment, due to its mature healthcare infrastructure, high cancer screening volumes, and rapid adoption of digital pathology. The United States government is strengthening cancer diagnostic technologies through the National Cancer Institute. According to the American Cancer Society, approximately 2.04 million new cancer cases are expected in the United States during 2025, sustaining strong demand for histopathology testing. In January 2025, Roche received approval from the FDA for its digital pathology scanner the VENTANA DP 600, which is used in clinics. Leading companies such as Thermo Fisher Scientific, Danaher, Agilent Technologies, Bio-Rad, and Waters are investing in pathology automation AI-enabled imaging and laboratory informatics, reinforcing North America's leadership in technology adoption and equipment replacement.
Asia-Pacific is the fastest growing market as governments prioritize cancer diagnosis, healthcare modernization, and domestic life sciences manufacturing. China is expanding its pathology laboratories and hospital infrastructure through its Healthy China 2030 strategy. Japan is enhancing its healthcare by changing its regulations. India is strengthening diagnostic capacity under the Ayushman Bharat program alongside continuous investments in AIIMS institutions, medical colleges, and public diagnostic laboratories. The International Agency for Research on Cancer states that Asia has half of the world's cancer cases, creating sustained demand for histopathology services
The competition is shifting from making standalone histopathology instruments to creating integrated digital pathology systems, that include tissue processing, slide scanning, immunohistochemistry, laboratory information systems, cloud connectivity, and artificial intelligence. Major companies such as Roche, Danaher, Thermo Fisher Scientific, Agilent Technologies, Sakura Finetek, Fujifilm, Shimadzu, and Bio-Rad are developing these systems., product innovations, software integrations, and strategic collaborations. In 2025, Roche strengthened its competitive position through FDA clearance of the VENTANA DP 600 scanner, supporting high-volume digital pathology workflows, while Thermo Fisher Scientific continues to expand precision oncology capabilities through investments in molecular diagnostics and pathology solutions. As demand for precision diagnostics and early disease detection continues to rise, histopathology testing equipment remains a critical component of modern healthcare systems, supporting clinical decision-making across hospitals, diagnostic laboratories, and research institutions.
In 2025, Roche continued advancing its Navify Digital Pathology ecosystem by expanding AI-supported pathology capabilities and companion diagnostic integration for oncology, reinforcing precision medicine and digital pathology adoption.
In 2025, Fujifilm expanded its AI-enabled digital pathology portfolio by advancing whole-slide imaging technologies and intelligent workflow solutions, enabling pathology laboratories to improve diagnostic efficiency, streamline case management, and support more informed clinical decision-making.